Which has the lower trailing P/E, AMRX or DOCS?

DOCS has the lower trailing P/E: AMRX trades at 41.67 and DOCS at 33.44. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, AMRX or DOCS?

Over the past five years, DOCS grew revenue faster — AMRX at a 8.67% CAGR versus DOCS at 21.94%.

Is AMRX or DOCS more profitable?

DOCS runs the higher net margin — AMRX at 5.05% versus DOCS at 25.48%.

How have AMRX and DOCS total returns compared?

Over the past 5 years, AMRX delivered 30.25% and DOCS delivered -18.23% annualized total return. Past performance doesn't predict future results.

Amneal Pharmaceuticals, Inc. (AMRX) vs Doximity, Inc. (DOCS)

A side-by-side comparison of Amneal Pharmaceuticals, Inc. and Doximity, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AMRX

Amneal Pharmaceuticals, Inc.

$6.49B

$20.31HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

DOCS

Doximity, Inc.

$5.32B

$28.43HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

Total return — AMRX vs DOCS

growth of $100 · dividends reinvested · last 5y

AMRX +276.2% (+30.3%/yr)DOCS -46.1% (-11.6%/yr)AMRX compounded faster over this window

Log scale — wide-divergence pair

AMRX DOCS

AMRX vs DOCS: by the numbers

•AMRX is the larger company ($6.49B vs $5.32B market cap).
•DOCS trades at the lower trailing earnings multiple (33.44 vs 41.67 P/E), one valuation lens rather than an overall verdict.
•DOCS converts more revenue to profit (25.48% vs 5.05% net margin).
•DOCS grew revenue faster over the past five years (21.94% vs 8.67% CAGR).

Metrics side by side

Valuation

Metric	AMRX	DOCS
P/E ratio	41.67	33.44
Forward P/E	19.84	21.10
PEG ratio	N/A	0.64
P/S ratio	2.08	8.11
P/B ratio	196.41	5.80
EV / EBITDA	15.31	23.87
FCF yield	1.28%	5.63%

Profitability

Metric	AMRX	DOCS
Gross margin	39.32%	88.07%
Operating margin	12.93%	29.60%
Net margin	5.05%	25.48%
ROE	476.51%	18.24%
ROIC	13.45%	15.35%

Growth (annualized)

Metric	AMRX	DOCS
Revenue CAGR (5Y)	8.67%	21.94%
EPS CAGR (5Y)	-17.72%	54.32%
FCF CAGR (5Y)	-14.46%	23.75%
Total return CAGR (5Y)	30.25%	-18.23%

Frequently asked

Which has the lower trailing P/E, AMRX or DOCS?: DOCS has the lower trailing P/E: AMRX trades at 41.67 and DOCS at 33.44. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, AMRX or DOCS?: Over the past five years, DOCS grew revenue faster — AMRX at a 8.67% CAGR versus DOCS at 21.94%.
Is AMRX or DOCS more profitable?: DOCS runs the higher net margin — AMRX at 5.05% versus DOCS at 25.48%.
How have AMRX and DOCS total returns compared?: Over the past 5 years, AMRX delivered 30.25% and DOCS delivered -18.23% annualized total return. Past performance doesn't predict future results.

Go deeper

Full AMRX analysis Full DOCS analysis Interactive comparison tool

Dig into the metrics

Amneal Pharmaceuticals P/E ratio Doximity P/E ratio Amneal Pharmaceuticals ROE Doximity ROE Amneal Pharmaceuticals operating margin Doximity operating margin Amneal Pharmaceuticals revenue growth Doximity revenue growth Amneal Pharmaceuticals free cash flow Doximity free cash flow

Amneal Pharmaceuticals & Doximity appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.